ST2 Fast Test Kit

(Immunofluorescence Assay)

Intended Use

ST2 Fast Test Kit (Immunofluorescence Assay) is intended for in vitro quantitative determination of ST2 in serum, plasma or whole blood samples. The test is indicated to be used in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure.

About ST2

ST2 (growth Stimulation expressed gene 2) is a novel cardiovascular biomarker and it is a member of the interleukin-1 receptor family. ST2 exists in 2 isoforms: a transmembrane bound form (ST2L) and a soluble form (sST2). Interleukin-33 (IL-33) is the ligand for both isoforms. When sST2 levels are low, IL-33 is available to bind to ST2L and has a cardioprotective effect resulting in preserved cardiac function. When sST2 levels are high, sST2 competitively binds to IL-33, making IL-33 less likely to bind to ST2L and thereby making it unavailable for cardioprotective signaling. As a result, the heart is subjected to greater stress in the presence of high levels of sST2, leading to cellular death and tissue fibrosis, reduced cardiac function, and an increase in the rate of disease progression.

Contents

1. For Getein1100

Package specifications: 25 tests/box, 10 tests/box

1) Getein ST2 test card in a sealed pouch with desiccant

2) Disposable pipet

3) Sample diluent

4) User manual: 1 piece/box

5) SD card: 1 piece/box

2.For Getein1600

Package specifications: 2×24 tests/kit, 2×48 tests/kit

1) Sealed cartridge with 24/48 Getein ST2 test cards

2) User manual: 1 piece/box

Materials required for Getein1600:

1) Sample diluent: 1 bottle/box

2) Box with pipette tips: 96 tips/box

3) Mixing plate: 1 piece/box

Note: Do not mix or interchange different batches of kits.

Specifications

Applicable Device

Getein1100 Immunofluorescence Quantitative Analyzer

Getein1600 Immunofluorescence Quantitative Analyzer

Clinical Application

1. As an aid in assessing the prognosis of patients diagnosed with chronic heart failure.

2. Reflect the degree of endomyocardial fibrosis (EMF).

3. As an aid in the monitoring of the treatment.